Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUSGet Free Report) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $41.25.

RCUS has been the subject of several recent research reports. Truist Financial reaffirmed a “buy” rating and set a $50.00 price target on shares of Arcus Biosciences in a report on Monday, March 25th. Mizuho reduced their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, January 30th. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of Arcus Biosciences in a research note on Thursday, May 9th.

Check Out Our Latest Report on RCUS

Insider Activity

In related news, President Juan C. Jaen sold 3,900 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $20.06, for a total transaction of $78,234.00. Following the sale, the president now owns 1,211,365 shares of the company’s stock, valued at $24,299,981.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, President Juan C. Jaen sold 3,900 shares of Arcus Biosciences stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the completion of the transaction, the president now directly owns 1,211,365 shares of the company’s stock, valued at $24,299,981.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Jennifer Jarrett sold 13,449 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $17.92, for a total value of $241,006.08. Following the completion of the sale, the chief operating officer now directly owns 226,804 shares in the company, valued at approximately $4,064,327.68. The disclosure for this sale can be found here. Insiders sold 53,455 shares of company stock worth $1,014,779 in the last 90 days. 12.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC acquired a new stake in shares of Arcus Biosciences in the fourth quarter valued at approximately $31,000. Public Employees Retirement System of Ohio purchased a new stake in Arcus Biosciences in the 3rd quarter valued at approximately $36,000. Spartan Fund Management Inc. acquired a new stake in Arcus Biosciences during the 1st quarter valued at $38,000. Strs Ohio acquired a new stake in Arcus Biosciences during the 3rd quarter valued at $43,000. Finally, Headlands Technologies LLC acquired a new position in shares of Arcus Biosciences in the first quarter worth $59,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $16.85 on Thursday. The stock has a market cap of $1.53 billion, a P/E ratio of -5.42 and a beta of 0.91. Arcus Biosciences has a 1-year low of $12.95 and a 1-year high of $25.47. The firm has a fifty day moving average price of $16.72 and a 200 day moving average price of $16.67.

Arcus Biosciences (NYSE:RCUSGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.92. Arcus Biosciences had a negative return on equity of 40.98% and a negative net margin of 97.47%. The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $28.77 million. During the same period in the prior year, the business earned ($1.09) EPS. The firm’s revenue was up 480.0% compared to the same quarter last year. Sell-side analysts expect that Arcus Biosciences will post -3.02 EPS for the current fiscal year.

Arcus Biosciences Company Profile

(Get Free Report

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

See Also

Analyst Recommendations for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.